Postoperative Accelerated Radiotherapy with Cytoprotection Followed by Three-Dimensional Conformal Boost in Patients with Early Endometrial/Cervical Cancer
Restricted accessResearch articleFirst published online July, 2009
Postoperative Accelerated Radiotherapy with Cytoprotection Followed by Three-Dimensional Conformal Boost in Patients with Early Endometrial/Cervical Cancer
Adjuvant external beam radiotherapy is highly recommended for uterine carcinomas invading beyond the inner half of the myometrium or cervical stage IIa carcinomas. The addition of a booster intracavitary dose is widely used.
Methods
We assessed the feasibility and toxicity of a hypofractionated accelerated conformal radiotherapy scheme (2.7 Gy per fraction, for 14 consecutive fractions to the pelvis) supported with the cytoprotective agent amifostine (HypoARC). The amifostine dose was individualized (500–1000 mg daily subcutaneously). A booster dose of radiation was given to the vagina and stump using a 6-field 3D-conformal technique (3 × 4 Gy or 4 × 3 Gy) instead of intracavitary radiotherapy.
Results
Grade 2 diarrhea appeared in 9/25 (36%) and grade 1 cystitis in 7/25 (28%) cases. Analysis according to the amifostine dose level clearly showed reduced toxicity in patients receiving a daily dose of 750–1000 mg (P <0.009). Within a median follow-up of 31 months (range, 11–52), there was only one case with grade 2 colitis (the patient had received no amifostine). None of the patients treated has relapsed locally or to distant organs within a median of 31 months of follow-up.
Conclusions
It is concluded that HypoARC followed by 3D-conformal booster dose to the vagina is feasible and convenient for patients and for busy radiotherapy departments, as it reduces the overall time by 50%. When supported by high-dose daily amifostine, it has an impressively low rate of early and late radiation toxicity.
WeissE., HirnleP., Arnold-BofingerH., HessC.F., BambergM.: Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. Radiother Oncol, 53: 37–44, 1999.
2.
IrwinC., LevinW., FylesA., PintilieM., ManchulL., KirkbrideP.: The role of adjuvant radiotherapy in carcinoma of the endometrium - results in 550 patients with pathologic stage I disease. Gynecol Oncol, 70: 247–54, 1998.
3.
LukkaH., ChambersA., FylesA., ThephamongkholK., Fung-Kee-FungM., ElitL., KwonJ., On behalf of the Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group: Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review. Gynecol Oncol, 10: 361–368, 2006.
4.
ScholtenA.N., van PuttenW.L., BeermanH., SmitV.T., KoperP.C., LybeertM.L., JobsenJ.J., Warlam-RodenhuisC.C., DeWinterK.A., LutgensL.C., van LentM., CreutzbergC.L., PORTEC Study Group: Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys, 63: 834–838, 2005.
5.
KeysH.M., RobertsJ.A., BrunettoV.L., ZainoR.J., SpirtosN.M., BlossJ.D., PearlmanA., MaimanM.A., BellJ.G.; Gynecologic Oncology Group: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate-risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 92: 744–51, 2004.
6.
MundtA.J., MellL.K., RoeskeJ.C.: Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys, 56: 1354–60, 2003.
7.
HeronD.E., GersztenK., SelvarajR.N., KingG.C., SonnikD., GallionH., ComerciJ., EdwardsR.P., WuA., AndradeR.S., KalnickiS.: Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small-star, filled. Gynecol Oncol, 91: 39–45, 2003.
8.
EinhornN., TropeC., RidderheimM., BomanK., SorbeB., Cavallin-StahlE.: A systematic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta Oncol, 42: 546–56, 2003.
9.
RotmanM., SedlisA., PiedmonteM.R., BundyB., LentzS.S., MuderspachL.I., ZainoR.J.: A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynaecologic oncology group study. Int J Radiat Oncol Biol Phys, 65: 169–76, 2006.
10.
GrevenK.M., D'AgostinoR.B.Jr., LancianoR.M., CornB.W.: Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer?Int J Radiat Oncol Biol Phys, 42: 101–104, 1998.
11.
BlissP., CowieV.J.: Endometrial carcinoma: does the addition of intracavitary vault caesium to external beam therapy postoperatively result in improved control or increased morbidity?Clin Oncol (R Coll Radiol), 4: 373–376, 1992.
12.
LiuT., LiuY., HeS., ZhangZ., KligermanM.M.: Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer, 69: 2820–2825, 1992.
13.
KoukourakisM.I., KyriasG., KakolyrisS., KouroussisC., FrangiadakiC., GiatromanolakiA., RetalisG., GeorgouliasV.: Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol, 18: 2226–2233, 2000.
14.
AthanassiouH., AntonadouD., ColiarakisN., KouveliA., SynodinouM., ParaskevaidisM., SarrisG., GeorgakopoulosG.R., PanousakiK., KarageorgisP., ThrouvalasN., Oncology Hellenic Group: Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys, 56: 1154–1160, 2003.
15.
KoulouliasV.E., KouvarisJ.R., PissakasG., MallasE., AntypasC., KokakisJ.D., MatsopoulosG., MichopoulosS., MystakidouK., VlahosL.J.: Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. Int J Radiat Oncol Biol Phys, 62: 486–493, 2005.
16.
MaciejewskiB., TaylorJ.M., WithersH.R.: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol, 7: 323–326, 1986.
17.
KoukourakisM.I., AbatzoglouI., SivridisL., TsarkatsiM., DelidouH.: Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res, 26: 2437–2443, 2006.
18.
BarakatR.R., LevG., HummerA.J., SonodaY., ChiD.S., AlektiarK.M., Abu-RustumN.R.: Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol, 105: 150–156, 2007.
KeysH.M., RobertsJ.A., BrunettoV.L., ZainoR.J., SpirtosN.M., BlossJ.D., PearlmanA., MaimanM.A., BellJ.G., Gynecologic Oncology Group: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 92: 744–751, 2004.
21.
OrtonJ., BlakeP., on behalf of the ASTEC/EN.5 collaborators: Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. Proc Am Soc Clin Oncol, 2007 ASCO Annual Meeting, Abstr 5504.
22.
GrevenK., WinterK., UnderhillK., FontenesciJ., CooperJ., BurkeT.: Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol, 103: 155–159, 2006.
23.
ScholtenA.N., van PuttenW.L., BeermanH., SmitV.T., KoperP.C., LybeertM.L., JobsenJ.J., Wárlám-RodenhuisC.C., DeWinterK.A., LutgensL.C., van LentM., CreutzbergC.L., PORTEC Study Group: Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys, 63: 834–838, 2005.
24.
AndersonJ.M., SteaB., HallumA.V., RogoffE., ChildersJ.: High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. Int J Radiat Oncol Biol Phys, 46: 417–425, 2000.
25.
WithersH.R., TaylorJ.M., MaciejewskiB.: The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol, 27: 131–146, 1988.
26.
FylesA., KeaneT.J., BartonM., SimmJ.: The effect of treatment duration in the local control of cervix cancer. Radiother Oncol, 25: 273–279, 1992.
27.
GasinskaA., FowlerJ.F., LindB.K., UrbanskiK.: Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone. Acta Oncol, 43: 657–666, 2004.
28.
MollàM., EscudeL., NouetP., PopowskiY., HidalgoA., RouzaudM., LineroD., MiralbellR.: Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy?Int J Radiat Oncol Biol Phys, 62: 118–1124, 2005.
29.
CreutzbergC.L., van PuttenW.L., KoperP.C., LybeertM.L., JobsenJ.J., Warlam-RodenhuisC.C., De WinterK.A., LutgensL.C., van den BerghA.C., van der Steen-BanasikE., BeermanH., van LentM., PORTEC Study Group: The morbidity of treatment for patients with stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys, 51: 1246–1255, 2001.
30.
HensleyM.L., HagertyK.L., KewalramaniT., GreenD.M., MeropolN.J., WassermanT.H., CohenG.I., EmamiB., GradisharW.J., MitchellR.B., ThigpenJ.T., TrottiA3rd, von HoffD., SchuchterL.M.: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol, 27: 127–145, 2009.
